‘Auric’ Relied On Amazon Reviews For Research Claims To Cure Fatty Liver

Ranchi : Patanjali’s case is going on in the Supreme Court for misleading people by showing misleading advertisements. But there are many other pharmaceutical companies in this category.

In fact, the Supreme Court has recently reprimanded Patanjali Ayurveda for misleading advertisements. Besides, the court has also ordered Baba Ramdev and Acharya Balakrishna to apologise. The case will be heard again on April 23.

Regarding another such case, Ranchi’s famous and young Dr. Anuj has posted a post on social media X. Which needs to be read and thought about and made aware.

Dr. Anuj has written, there is a company named Auric which itself manufactures Ayurvedic nutraceutical products. It has claimed in the advertisement of this company that it completely cures fatty liver within 60 days. It also claims to completely cure lung problems caused by cigarettes and other intoxicants. It claims to call its products in Nutraceuticals category.

They say that they have launched these products in the market after doing a lot of research. If these are nutraceuticals then how are they claiming to cure the disease? Does this not fall in the category of misleading advertising?

When he was asked to share his research, he said that he has reviews on Amazon . Are Amazon and Google’s reviews research articles for them? What is the compulsion of FSSAI that all these misleading companies have been given free rein to play with people’s health?

Related Posts

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

The Team Meticulously averted the Risk of Thrombosis, Husband was Donor Delhi/NCR : Doctors at Yashoda Medicity have successfully performed a high-risk kidney transplant in a 28-year-old woman with Antiphospholipid…

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta, a UK-based clinical stage biotech, is differentiated clinical-stage oncology specialist, increasingly defined by continuing progress with its second-generation pre|CISION tumour-activated Peptide Drug Conjugate (PDC) platform. The lead Gen Two…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Puresta launches EVERQ, AI-powered skin-health platform

Puresta launches EVERQ, AI-powered skin-health platform

Stem cell therapy for autism only in approved clinical trials: Centre

Stem cell therapy for autism only in approved clinical trials: Centre